PoA = directional probability band (not FDA guidance).
Rule: FDA decision events get a %; data/webinars/conferences get N/A.
THE FRAME (MAR 2–8): “POST-WEEKEND WALL → ONE CLEAN CMC CLOCK + ONE CONFERENCE ON-RAMP”
Last Monday was built around Saturday clocks — that wall has now printed, and the tape simplifies:
Front-half: post-meeting digestion (CLDX/AAAI; TARA/ASCO GU aftermath) + positioning trades.
Back-half: one clean FDA clock: $LNTH ( ▲ 0.53% ) (PYLARIFY new formulation) PDUFA Fri Mar 6.
On-ramp: MDA conference begins Mar 8 with $CAPR ( ▼ 3.97% ) HOPE-3 late-breaker slated Mar 11 (2:45pm ET).
WEEKEND WALL: WHAT CHANGED
The achondroplasia binary is over — the trade shifts to label specifics + launch execution + positioning vs Voxzogo.
REGN/SNY — $REGN ( ▲ 0.58% ) | Dupixent (AFRS) | Approved Tue Feb 24 | PoA: N/A (resolved)
Now a practice-pattern adoption story. Keep claims tight (“approved for AFRS” is enough; avoid “only therapy” phrasing unless you want to quote the press release).
(Carry-forward: $VNDA and $ETON already printed last week; no longer overhang items.)
THIS WEEK’S HARD EVENTS (IN ORDER)
Fri Mar 6 — LNTH — $LNTH ( ▲ 0.53% ) | PYLARIFY (piflufolastat F-18) new formulation | PDUFA | PoA: 92
This is a CMC/manufacturing optimization review (not a new clinical efficacy bet).
What to listen for:
any surprise CMC language / conditions
any supply or batch-size framing (access + resilience)
NEXT-UP CONFERENCE CATALYST (PUT ON DECK)
CAPR — $CAPR ( ▼ 3.97% ) | Deramiocel (DMD) | MDA Mar 8–11; late-breaking oral Mar 11 (2:45pm ET) | PoA: N/A
This week is the start of the catalyst window. Key intel: Capricor says it has submitted the HOPE-3 clinical study report (CSR) to the FDA — the submission was requested and is intended to address items outlined in the CRL and support the ongoing BLA review, including the potential assignment of a new PDUFA target action date.
DATA / CONFERENCE AFTERSHOCKS (NOW TRADING NARRATIVE)
CLDX — $CLDX ( ▲ 0.03% ) | barzolvolimab | AAAAI (Feb 27–Mar 2) | PoA: N/A
AAAI is now real-data tape. Watch durability + retreatment behavior (that’s where “best-in-disease” either holds or breaks).
TARA — $TARA ( ▼ 1.73% ) | TARA-002 (NMIBC) | ASCO GU | PoA: N/A
The market argument is durable CR, not any-time response. If you cite the 6-month number, pair it with “durability/maturity is the debate.”
ANY-DAY-NOW WILDCARDS (MARCH TIMING, NOT DAY-CERTAIN)
CVKD — $CVKD ( ▼ 1.18% ) | CAD-1005 (HIT) | End-of-Phase 2 FDA meeting expected in March | PoA: N/A
Not a print, but any signal on Phase 3 endpoint alignment / registrational path can move a microcap.
RYTM — $RYTM ( ▲ 0.56% ) | IMCIVREE (AHO) | PDUFA Mar 20 | PoA: 78
Rhythm put out additional positive TRANSCEND data Mar 1 — sentiment support into the March 20 clock.
WEEKLY CALENDAR (ONE SCREEN, WITH PoA)
Date | Ticker | Catalyst | PoA |
|---|---|---|---|
Now (through Mar 2) | AAAAI data aftermath (durability/retreatment narrative) | N/A | |
Now | ASCO GU aftermath (durability debate) | N/A | |
Fri Mar 6 | PDUFA — PYLARIFY new formulation (CMC) | 92 | |
Mar 8–11 | MDA (HOPE-3 LBO Mar 11) | N/A | |
Fri Mar 20 | PDUFA — IMCIVREE AHO expansion | 78 |
WEEKLY POSTURE (ONE PARAGRAPH)
Volatility this week is mostly narrative digestion (CLDX AAAAI + TARA durability debate), with one clean, high-probability FDA clock on $LNTH Mar 6 (CMC/formulation). The next true “tape change” starts Sunday as MDA week begins and positioning builds into $CAPR HOPE-3 late-breaker (Mar 11).
Tools we use: Market Chameleon (options/IV + unusual activity). We may earn a commission at no extra cost to you.
Disclaimer: informational only; not investment advice; biotech carries risk of total loss